Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transplant Proc ; 50(2): 683-684, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29579888

ABSTRACT

Infections in transplanted patients are still an important cause of morbidity and mortality. Among them, fungal infections with pathogens have become increasingly more prevalent in the last decade. We report the clinical course and management of disseminated Scedosporium apiospermum infection in a kidney transplant recipient, with microbiological isolation of the fungus in cerebrospinal fluid culture. S apiospermum is a fungus that is distributed worldwide and can be grown from soil samples or stagnant water. Disseminated infection is the most frequent form of infection, with cerebral involvement in most cases, which leads to a very high mortality (around 75%). Post-transplant renal infections require a thorough evaluation. Specifically, a high suspicion index is necessary, considering Scedosporium infection among the differential diagnosis of invasive fungal diseases in renal transplantation patients. It is essential to confirm the microbiological diagnosis for an adequate diagnosis and treatment.


Subject(s)
Immunocompromised Host , Kidney Transplantation/adverse effects , Mycoses/immunology , Postoperative Complications/immunology , Aged , Antifungal Agents/therapeutic use , Fatal Outcome , Humans , Male , Mycoses/diagnosis , Mycoses/drug therapy , Postoperative Complications/diagnosis , Postoperative Complications/microbiology , Scedosporium , Transplant Recipients
2.
Transplant Proc ; 47(9): 2622-5, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26680053

ABSTRACT

INTRODUCTION: Multiple factors are associated with post-transplantation anemia, and renal function is the main factor. The aims of this study were to compare the evolution of hemoglobin in the first year post-transplantation according to darbepoetin (DA) treatment, and factors related to it, to evaluate the difference between earlier versus delayed treatment, and to describe the dose change pattern. PATIENTS AND METHODS: We describe a retrospective study of cohorts in 462 transplant recipients (2004-2011). The variables reported were from donor, transplantation recipient, and DA treatment. RESULTS: In this study, 67.5% of patients were treated with DA, 32.5% were not. The comparison of hemoglobin in both groups during the first year showed a similar evolution with significant differences between consecutive measures until the second trimester. The hemoglobin of the treated group was significantly lower. The evolution of renal function was not different. Multivariate analysis related DA treatment to delayed graft function (DGF) and albuminuria in the first year. Patients with early versus delayed DA introduction did not show a difference regarding length of treatment, but the total dose in the delayed introduction was lower. The evolution of creatinine and hemoglobin was similar in both groups. CONCLUSION: The introduction of DA was related to DGF and albuminuria. The delayed introduction of DA meant the following: less total dose than earlier introduction, no difference in length of treatment, and a similar evolution in hemoglobin and renal function in both groups. The lack of guidelines about DA treatment in renal transplantation makes it difficult to establish a pattern of dose adjustment.


Subject(s)
Darbepoetin alfa/therapeutic use , Delayed Graft Function/drug therapy , Kidney Transplantation/adverse effects , Delayed Graft Function/etiology , Female , Follow-Up Studies , Hematinics/therapeutic use , Humans , Male , Middle Aged , Retrospective Studies , Time Factors , Treatment Outcome
3.
Transplant Proc ; 45(10): 3620-3, 2013.
Article in English | MEDLINE | ID: mdl-24314976

ABSTRACT

BACKGROUND: Infectious disease, a complication favored by immunosuppression, is the main cause of 1st-year mortality in solid organ transplantation. In renal transplant recipients (RTRs), urinary tract infection (UTI) is the most common, and the microorganisms that are isolated depend on chronology. METHODS: We present an observational study comprising 129 RTRs from January 2010 to December 2011 who were followed during the 1st year after transplantation. We analyzed occurrence of infections, predisposing factors, timing, severity, site of infection, and microorganisms. RESULTS: The patients had a total of 424 infectious episodes during the 1st year (3.29 episodes/patient/year). The predominant focus was the urinary tract, with at least 1 episode in 69.8% of patients. Bacteremia was recorded in 25.6% of patients and surgical wound infection in 20.9%. Cytomegalovirus infection or disease was diagnosed in 46.5%. Severe infections occurred in 30.2%. The predominant pathogen was E. coli. There was a significant correlation between hospital stay and the number of infections (P = .000; r = 0.407) and between body mass index and hospital stay (P = .001; r = 0.282). Severe infections were more frequent in diabetics, patients with a double-J stent, and those treated with basiliximab. Patients with cytomegalovirus replication had a higher number of infections (4.1 ± 1.2 vs 2.5 ± 5; P = .000) and significantly higher annual serum creatinine (1.65 ± 5.7 vs 1.31 ± 1.3 mg/dL; P = .003). CONCLUSIONS: The prevalence of infections in the 1st year after kidney transplantation is very high, occurring mainly in the early period, in the urinary tract, and due to E. coli. Cytomegalovirus replication is associated with a higher number of infections and higher serum creatinine at 1 year. Body mass index is a predictor of early infection and of bacteremia in the post-transplantation period. Basiliximab induction and having a double-J stent were predictors of severe infections.


Subject(s)
Communicable Diseases/epidemiology , Kidney Transplantation/adverse effects , Adult , Antibodies, Monoclonal/adverse effects , Basiliximab , Biomarkers/blood , Body Mass Index , Communicable Diseases/diagnosis , Communicable Diseases/microbiology , Communicable Diseases/virology , Creatinine/blood , Cytomegalovirus Infections/epidemiology , Cytomegalovirus Infections/virology , Diabetes Complications/etiology , Escherichia coli Infections/epidemiology , Escherichia coli Infections/microbiology , Humans , Immunosuppressive Agents/adverse effects , Length of Stay , Male , Prevalence , Recombinant Fusion Proteins/adverse effects , Risk Factors , Severity of Illness Index , Spain , Stents/adverse effects , Time Factors , Treatment Outcome , Urinary Tract Infections/epidemiology , Urinary Tract Infections/microbiology , Urinary Tract Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...